Kids & teens (for parents) · Texas
Studies for children and teens in Texas
These studies only enroll people under 18. A parent or legal guardian gives permission, and children old enough to understand are asked for their own agreement (assent).
128 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Eli Lilly and Company
- Location
- Beaumont, TX + 11 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
H. Lundbeck A/S
- Location
- San Antonio, TX + 8 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 1/Phase 2
DFT383 in Pediatric Participants With Nephropathic Cystinosis
Novartis Pharmaceuticals
- Location
- Houston, TX + 5 other US sites
- Eligibility basics
- Ages 2–5
- RecruitingPhase 2/Phase 3
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
Crinetics Pharmaceuticals Inc.
- Location
- Fort Worth, TX + 9 other US sites
- Eligibility basics
- Ages 1–17
- Recruiting
Infant Formula in Infants and Children With Cow's Milk Allergy
Abbott Nutrition
- Location
- Dallas, TX + 7 other US sites
- Eligibility basics
- Ages 4 mo–12
- RecruitingPhase 2
A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)
Pfizer
- Location
- Houston, TX + 10 other US sites
- Eligibility basics
- Up to age 10 mo
- RecruitingPhase 3
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Pfizer
- Location
- Corpus Christi, TX + 18 other US sites
- Eligibility basics
- Ages 6–14
- RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Garland, TX + 12 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec
Biogen
- Location
- Flower Mound, TX
- Eligibility basics
- Ages 0 mo–7 mo
- RecruitingPhase 3
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Pfizer
- Location
- Dallas, TX + 28 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
H. Lundbeck A/S
- Location
- San Antonio, TX + 13 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
H. Lundbeck A/S
- Location
- San Antonio, TX + 8 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
AstraZeneca
- Location
- Dallas, TX + 18 other US sites
- Eligibility basics
- Ages 5–11
- RecruitingPhase 3
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
Sanofi
- Location
- Austin, TX + 14 other US sites
- Eligibility basics
- Ages 6 mo–17
- RecruitingPhase 3
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
AstraZeneca
- Location
- Austin, TX + 70 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 1
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
Novartis Pharmaceuticals
- Location
- El Paso, TX + 10 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 1
Safety, PK and PD of FLQ-101 in Premature Neonates
FELIQS INC.
- Location
- Austin, TX
- Eligibility basics
- Ages 0 mo–0 mo
- RecruitingPhase 1
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Merck Sharp & Dohme LLC
- Location
- Houston, TX + 20 other US sites
- Eligibility basics
- Up to age 17
- RecruitingPhase 2
A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma
AstraZeneca
- Location
- Lewisville, TX + 11 other US sites
- Eligibility basics
- Ages 4–11
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
Axsome Therapeutics, Inc.
- Location
- Austin, TX + 28 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
Axsome Therapeutics, Inc.
- Location
- Austin, TX + 27 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
AbbVie
- Location
- Austin, TX + 28 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 2
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Incyte Corporation
- Location
- Bellaire, TX + 23 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 2
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
argenx
- Location
- Flower Mound, TX + 10 other US sites
- Eligibility basics
- Ages 5–17